clinical trial · NCT07440225
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Macular DegenerationAge-Related Macular DegenerationChoroidal NeovascularizationWet Macular DegenerationTiespectusAflibercept
brief summary
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.
started
Mar 27, 2026
primary completion
Jun 30, 2028
completion
Jun 30, 2028
last updated
Jun 30, 2026
official title
A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol